Guidelines for the Management of Mucopolysaccharidosis Type I

Journal of Pediatrics

Volumn 155, Issue 4 SUPPL., 2009, Pages

  Martins, Ana Maria ^a   Dualibi, Ana Paula ^a   Norato, Denise ^b   Takata, Edna Tiemi ^a   Santos, Emerson S ^c   Valadares, Eugênia Ribeiro ^d   Porta, Gilda ^e   de Luca, Gisele ^f   Moreira, Gustavo ^a   Pimentel, Helena ^g   Coelho, Janice ^h   Brum, Jaime Moritz ⁱ   Filho, José Semionato ^j   Kerstenetzky, Marcelo Soares ^k   Guimarães, Márcia R ^d   Muñoz Rojas, Maria Verónica ^l   Aranda, Paulo Cesar ^m   Pires, Ricardo Flores ⁿ   Faria, Rodrigo G C ^o   Mota, Ronald Moura Vale ^o   Matte, Ursula ^l   Guedes, Zelita Caldeira Ferreira ^a   more..

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^c UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

^g Associacao de Pais e Amigos dos Excepcionais de Sao Paulo   (Brazil)

^h FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ UFMG   (Brazil)

^j FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

^k HOSPITAL DA RESTAURAÇÃO   (Brazil)

^l HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^m Hospital Evangélico de Londrina   (Brazil)

ⁿ Clínica de Doenças Metabólicas Dr Ricardo Pires   (Brazil)

^o Hospital Geral Socor   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; CENTRAL MUSCLE RELAXANT; CETRIMIDE; CORTICOSTEROID; DECONGESTIVE AGENT; DIPHENHYDRAMINE; GLYCOSAMINOGLYCAN; HYDROXYZINE; IBUPROFEN; LARONIDASE; LEVO IDURONIDASE; PARACETAMOL; TOLONIUM CHLORIDE;

ADENOTONSILLECTOMY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANAMNESIS; ANESTHESIA; ANESTHESIA COMPLICATION; ARTICLE; BONE MARROW TRANSPLANTATION; CORNEA DISEASE; DAILY LIFE ACTIVITY; DISEASE REGISTRY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG STORAGE; EARLY INTERVENTION; ENZYME REPLACEMENT; EYE DISCHARGE; FOLLOW UP; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENE THERAPY; GENE TRANSFER; HEARING IMPAIRMENT; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; HYDROTHERAPY; INTUBATION; LARYNGOSCOPY; LASER SURGERY; LUNG FUNCTION TEST; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NOSE POLYP; NOSE SURGERY; PATIENT EDUCATION; PHYSIOTHERAPY; POLYSOMNOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RHINORRHEA; SCHEIE SYNDROME; SLEEP APNEA SYNDROME; SURVIVAL; TRACHEOSTOMY; TREATMENT RESPONSE; UVULOPALATOPHARYNGOPLASTY; VACCINATION;

BRAZIL; MUCOPOLYSACCHARIDOSIS I; PRACTICE GUIDELINES AS TOPIC;

EID: 70249125854     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.07.005     Document Type: Article

References (142)

1. Meikle P., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysossomal storage disorders. JAMA 281 (1999) 249-254
2. Lowry R.B., et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet 86 (1990) 389-390
3. Poorthuis B.J.H.M., et al. The frequency of lysosomal storage disease in the Netherlands. Hum Genet 105 (1999) 151-156
4. Moore D., Connock M.J., Wraith E., and Lavery C. The prevalence of and survival in mucopolysaccharidosis I: Hurler, Hurler-Scheie, and Scheie syndromes in the UK. Orphanet J Rare Dis 3 (2008) 24 [Epub ahead of print]
5. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C., Beaudet A., Sly W., et al. (Eds). The metabolic and molecular bases of inherited disease (2001), McGraw Hill, New York 3421-3452
6. Online Mendelian Inheritance in Man, OMIM. Johns Hopkins University, Baltimore, MD. MIM Number: 607014, last edited: 10/6/2003. Available at: http://www.ncbi.nlm.nih.gov/omim.
7. Wraith J.E. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 72 (1995) 263-267
8. Martins AM, et al. Mucopolissacaridoses: Manual de Orientações. Avaliable at: http://www.unifesp.br/centros/creim/downloads/gz-mps-apostila-2003.pdf.
9. Wraith J.E. MPS I management and treatment guidelines. Am J Hum Genet 73 (2003) 621
10. Shapiro J., Strome M., and Croker A.C. Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 94 (1985) 458-461
11. Carroll J.L., and Loughlin G.M. Obstructive sleep apnea syndrome in infants and children: diagnosis and management. In: Ferber R., and Kryger M. (Eds). Principles and practice of sleep medicine in the child (1995), W.B. Saunders Company, Philadelphia 193-216
12. Moreira GA., Pradella-Hallinan MC., Rueda AD, Barbisan BN, Tufik S. Nasal positive pressure for children with sleep disordered breathing. In: Latin American Sleep Congress, 8, Sao Paulo, 2000. Abstracts. Hypnos 2000;1:73.
13. Chan D., Li A.M., Yam M.C., Li C.K., and Fok T.F. Hurler's syndrome with cor pulmonale secondary to obstructive sleep apnoea treated by continuous positive airway pressure. J Pediatric Child Health 39 (2003) 558-559
14. American Thoracic Society. Indications and standards for cardiopulmonary sleep studies. Am Rev Respir Dis 139 (1989) 559-568
15. American Thoracic Society. Cardiorespiratory sleep studies in children. Establishment of normative data and polysomnographic predictors of morbidity. Am J Respir Crit Care Med 160 (1999) 1381-1387
16. Marcus C.L. Sleep-disordered breathing in children. Am J Respir Crit Care Med 164 (2001) 16-30
17. Mcnamara F., and Sullivan C.E. Obstructive sleep apnea in infants and its management with nasal continuous positive airway pressure. Chest 116 (1999) 10-16
18. Moreira GA, Pradella-Hallinan MC, Barbisan BN, Tufik S. Sleep disorders in children with mucopolysaccharidosis. In: Associated Professionals Sleep Society Annual Meeting, 15, Chicago, June 17-22, 2001. Abstracts. Sleep, 2001;24(abstract suppl):A210.
19. Guilleminault C., Pelayo R., Leger D., Clerk A., and Bocian R.C. Recognition of sleep-disordered breathing in children. Pediatrics 98 (1996) 871-882
20. Myer C.M. Airway obstruction in Hurler's syndrome: radiographic features. Int J Pediatr Otorhinolsryngol 22 (1991) 91-96
21. Casselbrant M.L. Methods of examination. In: Bluestone C.D., Stool S.E., and Kenna M.A. (Eds). Pediatric otolaryngology. 3rd ed (1996), W B Saunders Co, Philadelphia
22. Semenza G.L., and Pyeritz R.E. Respiratory complications of mucopolysaccharide storage disorders. Medicine 67 (1988) 209-219
23. Bredenkamp J.K., Smith M.E., Dudley J.P., Williams J.C., Crumley R.L., and Crockett D.M. Otolayngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Layngol 101 (1992) 472-478
24. Mac A., Glicklich R., McGill T.J.I., and Perez-Atayde A. Sinus complications in mucopolysaccharidoses I H/S (Hurler-Scheie syndrome). Int J Pediatr Otorhinolsryngol 26 (1993) 79-87
25. Wald E.R. Rhinitis and acute and chronic sinusitis. In: Bluestone C.D., Stool S.E., and Kenna M.A. (Eds). Pediatric otolaryngology. 3rd ed (1996), W B Saunders Co, Philadelphia
26. Nayak D.R., Balakrishnan R., and Adolph S. Endoscopic adenoidectomy in a case of Scheie syndrome. Int J Pediatr Otorhinolaryngol 44 (1998) 177-181
27. Wetmore R. Tracheotomy. In: Bluestone C.D., Stool S.E., and Kenna M.A. (Eds). Pediatric otolaryngology. 3rd ed (1996), W B Saunders Co, Philadelphia
28. Maddern B.R. Obstructive sleep disorders. In: Bluestone C.D., Stool S.E., and Kenna M.A. (Eds). Pediatric otolaryngology. 3rd ed (1996), W B Saunders Co, Philadelphia
29. Allen J.L. Treatment of respiratory system (not just lung!) abnormalities in mucopolysaccharidosis I. J Pediatr 144 (2004) 581-588
30. Shinhar S.Y., Zablocki H., and Madgy D.N. Airway management in mucopolysaccharide storage disorders. Arch Otolaryngol Head Neck Surg 130 (2004) 233-237
31. Ard J.L., Bekker A., and Frempong-Boadu A.K. Anesthesia for an adult with mucopolysaccharidosis I. J Clin Anesth 17 (2005) 624-626
32. Walker R.W.M., Colovic V., Robinson D.N., and Dearlove O.R. Postobstrutive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paed Anaesth 13C (2003) 441-447
33. Ruckenstein M.J., MacDonald R.E., Clarke J.T.R., and Forte V. The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review. J Otolaryngol 20 (1991) 177-183
34. Motamed M., Thorne S., and Narula A. Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 53 (2000) 121-124
35. Hayes E., Babin R., and Platz C. The otologic manifestatiosn of mucopolysaccharidoses. Am J Otol 2 (1980) 65-69
36. Friedmann I., Spellacy E., Crow J., and Watts R.W.E. Histopathological studies of the temporal bones in Hurler's disease. J Laryngol Otol 99 (1985) 29-41
37. Schachern P.A., Shea D.A., and Papparella M.M. Mucopolysaccharidoses IH (Hurler's syndrome) and human temporal bone histopatholoy. Ann Otol Rhinol Laryngol 93 (1984) 65-69
38. Oghan F., Harputluoglu U., Guclu E., Guvey A., Turan N., and Ozturk O. Permanent t-tube insertion in two patients with Hurler's syndrome. Int J Audiol 46 (2007) 94-96
39. Wraith J.E., and Cleary M.A. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Pediatr (1995)
40. Martins M., and Fonseca M.H. Repercussões psico-sociais na criança com Mucopolissacaridose. Acta Medica Portuguesa 5 (1995) 329-334
41. Becker E. Deficiências: alternativas de intervenção. Casa do Psicólogo 95 (1997) 31-52
42. Seto T., et al. Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 50 (2001) 79-92
43. Watts R.W.E., Spellacy E., Kendall B.E., du Boulay G., and Gibbs D.A. Computed tomography studies on patients with mucopolysaccharidoses. Neuroradiology 21 (1981) 9-23
44. Sheridan M., and Johnston. Hydrocephalus and pseudomotor cerebri in the mucopolysaccharidoses. Childs Nerv Syst 10 (1994) 148-150
45. Barone R., Parano E., Trifiletti R.R., Fiumara A., and Pavone P. White matter changes mimicking a leukodystrophy in a patient with mucopolysaccharidosis: characterization by MRI. J Neurolog Sci 195 (2002) 171-175
46. Herman M.J., and Pizzutillo P.D. Cervical spine disorders in children. Orthoped Clin North Am 30 (1999) 457-466
47. Taccone A., Donati P.T., Marzoli A., Acqua A.D., Gatti R., and Leone D. Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings. Pediatr Radiol 23 (1993) 349-352
48. Kachur E., and Maestro R.D. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery 47 (2000) 223-229
49. Dalvie S.S., Noorden F.R.C.S., and Vellodi A. Anterior instrumented fusion for thoracolumbar kyphosis in mucopolysaccharidosis. Spine 26 (2001) E539-E541
50. Pierpont M.E.M., and Moller J.H. Cardiac manifestations of genetic disease. In: Moss A. (Ed). Heart disease in infants, children, and adolescents. 5th ed (1995), Williams & Wilkins, London 1486-1520
51. Soliman O.I.I., Timmermans R.G.M., Nemes A., et al. Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. J Inherit Metab Dis (2007) Published online
52. Donaldson M.D.C., Pennock C.A., Berry P.J., et al. Hurler syndrome with cardiomyiopathy in infancy. J Pediatr 114 (1989) 430-432
53. Farina V., Leva F., Caso P., et al. Echo-Doppler abnormalities in mucopolysaccharide storage diseases. Acta Paediatr 81 (1992) 702-704
54. Mohan U.R., Hay A.A., Cleary M.A., et al. Cardiovascular changes in children with mucopysaccharide disorders. Acta Paediatr 91 (2002) 799-804
55. Dangel J.H. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157 (1998) 534-538
56. Rigante D., and Segni G. Cardiac structural involviment in mucopolysaccharidoses. Cardiology 98 (2002) 18-20
57. Fischer T.A., Lehr H.A., Nixdorff U., and Meyer J. Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome). Heart 81 (1999) 97-99
58. Minakata K., Konishi Y., Matsumoto M., and Miwa S. Surgical treatment for Scheie syndrome (mucopolysaccharidosis type I-S)-report of two cases. Jpn Circ J 62 (1998) 700-703
59. Belmont P.J. Early diagnosis of Hurler's syndrome with the aid of the identification of the characteristic gibbus deformity. Mil Med 10 (1998) 711-714
60. Matsui Y., Kawabata H., Nakayama M., Ozono, Keiichi, Kitoch H., et al. Sheie syndrome (MPS-IS) presented as bilateral trigger thumb. Pediatr Int (2003)
61. Grossman H. Progress in pediatric radiology, intrinsic desease of bones. In: Kaufmann HJ, editor. Philadelphia:1973. p. 495-544.
62. Taybi H., and Lachman R.S. Radiology of syndromes, metabolic disorders, and skeletal dysplasias (1996), Mosby p. 670-81
63. Khanna G., Van Heest A.E., Agel J., Bjoraker K., Grewal S., Abel S., et al. Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 39 (2007) 331-334
64. Haddad F.S., Jones D.H.A., Vellodi A., et al. Carpal tunel syndrome in the mucopolysaccharidoses. J Bone Joint Surg 79-B (1997) 576-582
65. Sillence D. Neurological complications of MPS. In: 4th International Symposium on Mucopolysaccharide and Related Diseases program. Wollongong, Australia (1996) p. 36
66. Masterson E.L., Murphy P.G., O'Meara A., Moore D.P., Dowling F.E., and Fogarty E.E. Hid dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Paediatr Orthopaed 16 (1996) 731-733
67. Wraith J.E., and Alani S.M. Carpal tunnel syndrome in the mucopolysaccharidosis and related disorders. Arch Dis Child 65 (1990) 962-963
68. Pronicka E., Tylki-Szymanska A., Kwast O., Chmielik J., Maciejko D., and Cedro A. Carpal tunnel syndrome in children with mucopolysaccharidoses: needs for surgical tendons and median nerve release. J Ment Defic Res 32 Pt 1 (1988) 79-82
69. Kakkis E.D., Muenzer J., Tiller G.E., et al. Enzyme replacement therapy in, ucopolysaccharidosis I. N Engl J Med 344 (2001) 182-188
70. Wraith J.E., Beck M., Lane R., et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha- L-iduronidase (laronidase). Pediatrics 120 (2007) e37-e46
71. Grupcheva C.N., Craig J., and McGhee N.J. In vivo microstructural analysis of the cornea in Schei's syndrome. Cornea 22 (2003) 76-79
72. Ashworth J.L., Biswas S., Wraith E., and Lloyd C. The ocular features of the mucopolysaccharidoses. Eye 20 (2005) 553
73. Ashworth J.L., Biswas S., Wraith E., and Lloyd C. Mucoppolysaccharidoses and the eye. Surv Ophthalmol 51 (2006) 1-17
74. Scott H.S., Ashton L.J., Eyre H.J., Baker E., Brooks D.A., Callen D.F., et al. Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3. Am J Hum Genet 47 (1990) 802-807
75. Scott H.S., Litjens T., Hopwood J.J., and Morris C.P. A common mutation for mucopolysaccharidosis type I associated with a severe Hurler phenotype. Hum Mutat 1 (1992) 103-108
76. Scott H.S., Guo X.H., Hopwood J.J., and Morris C.P. Structure and sequence of the human alpha-L-iduronidase gene. Genomics 13 (1992) 1311-1313
77. Scott H.S., et al. Alpha-L-iduronidase mutations (Q70X and P533R) associated with a severe Hurler phenotype. Hum Mutat 1 (1992) 333-339
78. Bunge S., Kleijer W.J., Steglich C., Beck M., Zuther C., Morris C.P., et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two commom alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet 3 (1994) 861
79. Gort L., and Chabs C.MJ. Analysis of five mutations in 20 mucopolysaccharidosis type I patients: high prevalence of the W402X mutation. Hum Mutat 11 (1998) 332
80. Voskoboeva E.Y., Krasnopolskaya X.D., Mirenburg T.V., Weber B., and Hopwood J.J. Molecular genetics of mucopolysaccharidosis type I: mutation analysis among the patients of the former Soviet Union. Mol Genet Metab 65 (1998) 174
81. Bach G., Moskowitz S.M., Tieu P.T., Matynia A., and Neufeld E.F. Molecular analysis of Hurler syndrome in Druze and Muslim patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. Am J Hum Genet 53 (1993) 330
82. Yamagishi A., Tomatsu S., Fukuda S., Uchiyama A., Shimozawa N., Susuki Y., et al. Mucopolysaccharidosis type I patients: identification of common mutations that cause Hurler and Scheie syndromes in Japanese populations. Hum Mutat 7 (1996) 23
83. Matte U., Yogalingam G., Brooks D., Leistner S., Schwatz I., Lima L., et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab 78 (2003) 37-43
84. Aronovich E.L., Pan D., and Whiteley C.B. Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency. Am J Hum Genet 58 (1996) 75-85
85. Chamoles N.A., Blanco M., and Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility 0f newborn diagnosis. Clin Chem 47 (2001) 780-781
86. Chamoles N.A., Blanco M., Gaggioli D., and Casentini C. Hurler-like phenotype: enzuimatic diagnosis in dried blood spots on filter paper. Clin Chem 47 (2001) 2098-2102
87. Pastores G.M., Arn P., Beck M., Clarke J.T., Guffon N., Kaplan P., et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab 91 (2007) 37-47
88. Hingston E.J., Hunter M.L., Hunter B., and Drage N. Hurler's syndrome: dental findings in a case treated with bone marrow transplantation in infancy. Int J Paediatr Dent 16 (2006) 207-212
89. Guven G., Cehreli Z.C., Altun C., Sencimen M., Ide S., Bayari S.H., et al. Mucopolysaccharidosis type I (Hurler syndrome): oral and radiographic findings and ultrastructural/chemical features of enamel and dentin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (Jun 27, 2007) [Epub ahead of print]
90. Dusing S.C., Thorpe D., Rosenberg A., Mercer V., and Escolar M.L. Gross motor abilities in children with Hurler syndrome. Dev Med Child Neurol 48 (2006) 927-930
91. Haley S.M., Fragala, Pinkham MA., Dumas H.M., Ni P., Skrinar A.M., et al. A physical performance measure for individuals with mucopolysaccharidosis type I. Dev Med Child Neurol 48 (2006) 576-581
92. Evangelista L.M.C. As novas abordagens do diagnóstico psicológico da deficiência mental. 1st ed (2002), Vetor, São Paulo p. 33-76, 217-50
93. Skinner-Thompson. Exercícios na água. São Paulo: Editora: Manole; 1985.
94. Kelly M., and Darrah J. Aquatic exercise for children with cerebral palsy. Dev Med Child Neurol 47 (2005) 838-842
95. Norm A., and Hanson B. Exercícios aquáticos terapêuticos. São Paulo: Manole (1998)
96. Ruoti R.G., Morris D.M., and Cole A.J. Efeitos fisiológicos da imersão em repouso. In: Bookspan J. (Ed). Reabilitação aquatica (2000), Manole, São Paulo 29-42
97. Schiffmann R., and Brady R.O. New prospects for the treatment of lysosomal storage diseases. Drugs 62 (2002) 733-742
98. Staba S.L., Escolar M.L., Poe M., Kim Y., Martin P.L., Szabolcs P., et al. Cord-bood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350 (2004) 1960-1969
99. Peters C., and Steward C.G. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 31 (2003) 229-239
100. Fujisaki G., Kami M., and Kishi Y. Cord-blood transplants from unrelated donors in Hurler's syndrome. N Engl J Med 350 (2004) 1960-1969
101. Baxter M.A., Wynn R.F., Schyma L., Holmes D.K., Wraith J.E., Fairbairn L.J., et al. Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development. J Inherit Metab Dis 28 (2005) 1045-1053
102. Church H., Tylee K., Cooper A., Thornley M., Mercer J., Wraith E., et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant 39 (2007) 207-210
103. Braunlin E.A., Rose A.G., Hopwood J.J., Candel R.D., and Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol 88 (2001) 1075-1077
104. Souillet G., Guffon N., Maire I., Pujol M., Taylor P., Sevin F., et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 31 (2003) 1105-1117
105. Braunlin E.A., Stauffer N.R., Peters C.H., Bass J.L., Berry J.M., and Hopwood J.J. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 92 (2003) 882-886
106. Taylor C., Brady P., O'Meara A., Moore D., Dowling F., and Fogarty E. Mobility in Hurler syndrome. J Pediatr Orthop 28 (2008) 163-168
107. Hugh-Jones K. Psychomotor development of children with mucopolysaccharidoses type 1-H following bone marrow transplantation. Birth Defects 22 (1986) 25
108. Peters C., Balthazor M., Shapiro E.G., King R.J., Kollman C., Hegland J.D., et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87 (1996) 4894-4902
109. Vellodi A., Young E.P., Cooper A., Wraith J.E., Winchester B., Meaney C., et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centers. Arch Dis Child 76 (1997) 92-99
110. Soni S. Allogeneic stem cell transplantation for genetic disorders. J Ky Med Assoc 105 (2007) 12-16
111. Fleming D.R., Henslee-Downey P.J., Ciocci G., Romond E.H., Marciniak E., Munn R.K., et al. The use of partially HLA-mismatched donors for allogenic transplantation in patients with mucopolysacharidosis-I. Pediatr Transplant 2 (1998) 299-304
112. Grewal S.S., Krivit W., Defor T.E., Shapiro E.G., Orchard P.J., Abel S.L., et al. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant 29 (2002) 491-496
113. Peters C., Shapiro E.G., Anderson J., Henslee-Downey P.J., Klemperer M.R., Cowan M.J., et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 91 (1998) 2601-2608
114. Lange M.C., Teive H.A., Troiano A.R., Bitencourt M., Funke V.A., Setúbal D.C., et al. Bone marrow transplantation in patients with storage diseases: a developing country experience. Arq Neuropsiquiatr 64 (2006) 1-4
115. Boelens J.J., Wynn R.F., O'Meara A., et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 40 (2007) 225-233
116. Grewal S.S., Wynn R., Abdenur J.E., Burton B.K., Gharib M., Haase C., et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 7 (2005) 143-146
117. Boelens J.J. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis 29 (2006) 413-420
118. Cox-Brinkman J., Boelens J.J., Wraith J.E., O'Meara A., Veys P., Wijburg F.A., et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 38 (2006) 17-21
119. Tolar J., Grewal S.S., Bjoraker K.J., et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant 41 (2007) 531-535
120. Kakkis E.D. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs 11 (2002) 675-685
121. Wraith J.E. Enzyme replacement therapy in mucopolysacccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 24 (2001) 245-250
122. United States Food and Drug Administration. Aldurazyme approval information. Available at (2003). http://www.fda.gov/cder/biologics/products/larobio043003.htm
123. European Agency for the Evaluation of Medical Products. Aldurazyme approval information. Available at (2003). http://www.emea.eu.int/humandocs/Humans/EPAR/aldurazyme/aldurazyme.htm
124. Giugliani R., Muñoz Rojas V., Martins A.M., Valadares E.R., Clarke J.T.R., Góes J., et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab (2008) In press
125. Clarke L., Wraith J.E., Beck M., et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics (2009) In press
126. Pastores G.M., Wraith J.E., Clarke L.A., et al. The clinical benefit of Aldurazyme (laronidase) for the treatment of MPS I. Am J Hum Genet 73 (2003) 624
127. Bajbouj M., Beck M., Wraith J.E., et al. Efficacy of Aldurazyme enzyme replacement therapy on joint mobility I MPS I. Am J Hum Genet 73 (2003) 621
128. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144 (2004) 561-562
129. Miebach E. Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr Suppl 94 (2005) 58-60
130. Wraith J.E. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6 (2005) 489-506
131. Wraith J.E., Hopwood J.J., Fuller M., Meikle P.J., and Brooks D.A. Laronidase treatment of mucopolysaccharidosis I. BioDrugs 19 (2005) 1-7
132. Braunlin E.A., Berry J.M., and Whitley C.B. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98 (2006) 416-418
133. Soutar R.L., Mercer J., and Wraith J.E. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient. J Inherit Metab Dis 29 (2006) 590
134. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90 (2007) 171-180
135. Sardón O., García Pardos C., Mintegui J., Pérez Ruiz E., Coll M.J., Chabás A., et al. Outcome of two patients with Hurler's syndrome under enzyme replacement therapy with human recombinant alpha-L-iduronidase. Ann Pediatr (Barc) 63 (2005) 61-67
136. Tokic V., Barisic I., Huzjak N., Petkovic G., Fumic K., and Paschke E. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr 166 (2007) 727-732
137. Anbu A.T., Mercer J., and Wraith J.E. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis 29 (2006) 230-231
138. Wegrzyn G., Tylki-Szymańska A., Liberek A., Piotrowska E., Jakóbkiewicz-Banecka J., Marucha J., et al. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet A 143 (2007) 1925-1927
139. Anson D.S., Bielicki J., and Hopwood J.J. Correction of mucopolysaccharidosis type I fibroblasts by retroviral-mediated transfer of the human alpha-L-iduronidase gene. Hum Gene Ther 3 (1992) 371-379
140. Hartung S.D., Frandsen J.L., Pan D., Koniar B.L., Graupman P., Gunther R., et al. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9 (2004) 866-875
141. Lutzko C., Kruth S., Abrams-Ogg A.C., Lau K., Li L., Clark B.R., et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 93 (1999) 1895-1905
142. Shull R.M., Lu X., McEntee M.F., Bright R.M., Pepper K.A., and Kohn D.B. Myoblast gene therapy in canine mucopolysaccharidosis. I: abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther 7 (1996) 1595-1603